← Russell 3000 cross-section

XERS Xeris Biopharma Holdings, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$1.6bn
Revenue TTM
$335m
Net income TTM
$-17m
Free cash flow
Composite score
48.2
Sector rank
#1768

Valuation

P / E
EV / EBITDA
43.5
EV / sales
4.9
FCF yield
Earnings yield vs 10-yr
-5.82pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-5.1%
EBITDA margin
11.3%
ROE
176.3%
ROIC
63.8%
Revenue growth
36.3%

Insider activity, last 90 days

Net open-market
$-2.04m
Buyers
0
Sellers
7

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Other income (expense) Other income (expense) consists primarily of interest expense related to our loan and convertible debt, interest income earned on deposits and investments. Results of Operations The following table summarizes our results of operations for the three and six months ended June 30, 2026 and 2025 (in thousands): Product revenue, net Recorlev Net revenue increased by $25.3 million or 80.6% for the three months ended June 30, 2026 compared to the three months ended June 30, 2025. The increase was due to higher volume ($21.9 million or 69.6%), primarily driven by increased patient demand, and favorable net pricing ($3.4 million or 11.0%). …Xeris Biopharma Holdings, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →